Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis

NCT03109236 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

66

Enrollment

OTHER

Sponsor class

Conditions

End Stage Liver Disease

Interventions

DRUG: GCSF
PROCEDURE: CD133 Cells Transplantation

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]
[object Object]
[object Object]